19 related articles for article (PubMed ID: 3181446)
1. The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.
Sottotetti F; Ferraris E; Tagliaferri B; Palumbo R; Quaquarini E; Teragni C; Balletti E; Leli C; Premoli A; Mollica L; Puglisi S; Sardi S; Malovini A; Pedrazzoli P; Bernardo A
Drugs Context; 2022; 11():. PubMed ID: 36118250
[TBL] [Abstract][Full Text] [Related]
2. Methodology and applications of disease biomarker identification in human serum.
Sahab ZJ; Semaan SM; Sang QX
Biomark Insights; 2007 Feb; 2():21-43. PubMed ID: 19662190
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of the role of five tumour markers in breast cancer.
Robertson JF; Pearson D; Price MR; Selby C; Pearson J; Blamey RW; Howell A
Cancer Immunol Immunother; 1991; 33(6):403-10. PubMed ID: 1878893
[TBL] [Abstract][Full Text] [Related]
4. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer.
Williams MR; Turkes A; Pearson D; Griffiths K; Blamey RW
Eur J Surg Oncol; 1990 Feb; 16(1):22-7. PubMed ID: 2137790
[TBL] [Abstract][Full Text] [Related]
5. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
[TBL] [Abstract][Full Text] [Related]
6. [Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)].
Pompecki R; Schröder G; Garbrecht M; Frahm H
Dtsch Med Wochenschr; 1978 Apr; 103(14):620-2. PubMed ID: 639696
[TBL] [Abstract][Full Text] [Related]
7. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Morgan LR
Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
[TBL] [Abstract][Full Text] [Related]
9. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review.
Williams MR; Turkes A; Pearson D; Twining P; Griffiths K; Blamey RW
Eur J Surg Oncol; 1988 Oct; 14(5):417-22. PubMed ID: 3181446
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen in breast cancer. Clinical review.
Beard DB; Haskell CM
Am J Med; 1986 Feb; 80(2):241-5. PubMed ID: 3511688
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
